Brandywine Global Investment Management LLC Lowers Stock Holdings in Genmab A/S Sponsored ADR $GMAB

Brandywine Global Investment Management LLC reduced its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 27.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,031,464 shares of the company’s stock after selling 381,371 shares during the quarter. Brandywine Global Investment Management LLC’s holdings in Genmab A/S were worth $31,769,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Osaic Holdings Inc. grew its stake in shares of Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the last quarter. NewEdge Advisors LLC grew its stake in shares of Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares during the last quarter. Brown Brothers Harriman & Co. grew its stake in shares of Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares during the last quarter. Founders Capital Management grew its stake in shares of Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Genmab A/S by 124.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after purchasing an additional 1,174 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GMAB has been the topic of several analyst reports. Guggenheim lowered their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Morgan Stanley started coverage on Genmab A/S in a report on Monday, February 16th. They set an “equal weight” rating and a $34.00 price objective for the company. Finally, HC Wainwright cut their price target on Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.93.

Genmab A/S Stock Performance

Genmab A/S stock opened at $24.80 on Tuesday. The firm has a market capitalization of $15.46 billion, a P/E ratio of 18.79, a PEG ratio of 1.49 and a beta of 0.85. The stock has a fifty day moving average price of $26.88 and a 200 day moving average price of $29.38. Genmab A/S Sponsored ADR has a 52 week low of $20.23 and a 52 week high of $35.43. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.